Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|January 26, 2022
Daily Medication Pearl: Efgartigimod alfa-fcab (Vyvgart)
Author(s)Saro Arakelians, PharmD
Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.
Advertisement
Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)
Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.
Insight:
- Dosing: The recommended dosage is 10 mg/kg administered as an intravenous infusion over 1 hour once weekly for 4 weeks.
- Dosage forms: Injection 400 mg in 20 mL (20 mg/mL) single-dose vial.
- Adverse events: Most common adverse reactions (≥ 10%) in patients treated with gMG are respiratory tract infections, headache, and urinary tract infection.
- Mechanism of action: Efgartigimod alfa-fcab is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.
- Manufacturer: Argenx
Sources:
Advertisement
Related to this article
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
Beyond Prescription Volume: Measuring the Pharmacist’s Value
5